Xcelience Opens New Development Facility

Xcelience LLC recently announced the grand opening of a new 24,000-sq-ft facility, located south of the Tampa airport at 4901 Grace Street. The building will be dedicated to primary and secondary packaging, labeling, distribution, and warehouse services.

Xcelience serves national and international clients in the biotech and pharmaceutical industries, offering cGMP services from preformulation and formulation through clinical manufacturing and clinical supplies for Phase I-III clinical trials. This is the company’s second facility in the Tampa Bay area, and it will be audited and approved for domestic as well as European clinical trials. The expansion also promises to open the door to more highly skilled jobs for the Tampa Bay Area.

“At Xcelience, we work on several dozens of molecules, each of which has the potential to radically improve people’s lives,” said Derek Hennecke, CEO and President. “We love being in Tampa because through USF, UF, and Tampa’s growing biotech community, we have access to scientists at the height of their fields. We don’t have to go far to find people who thrive on the challenge of working with different molecules, upholding rigorous FDA standards while also demonstrating the agility to meet client parameters for speed, cost, and efficiency.”

Xcelience has doubled its staff throughout the past 3 years and will soon be celebrating the hiring of the company’s 100th employee. The new plant will enable Xcelience to double its headcount again throughout the next 3 years.

“Tampa’s been called one of the best places to do business. Our health sciences cluster is creating the jobs of the future,” said Tampa Mayor Bob Buckhorn. “I am proud Xcelience calls Tampa home, and congratulate them on the opening of their second facility here.”

“Xcelience has been a wonderful addition to our business community, and we’re pleased to join them in celebrating the opening of their new facility,” said Rick Homans, President and CEO of the Tampa Hillsborough Economic Development Corporation. “Their continued growth and expansion is a testament to the quality of our workforce, and their presence is a significant asset as we work to expand our life sciences industry.”

Guests for the ceremony in addition to staff, clients, and corporate partners include Honorable Jack Latvala, Florida Senate, Tampa Mayor Bob Buckhorn, Honorable Al Higginbotham, Hillsborough County Board of County Commissioners, Honorable Dana Young, Florida House of Representatives, Julie Fitzpatrick from the office of Congresswoman Kathy Castor, and supporting members from the Tampa Hillsborough Economic Development Corporation and the Tampa Bay Partnership.

Xcelience wishes to thank the Florida institutions that have offered continued economic stimulation and sustained capital investment to Xcelience and other Florida companies like it. In particular: The Tampa Hillsborough Economic Development Corporation – officially designated by Enterprise Florida as Hillsborough County’s primary business recruitment economic development team; and The Tampa Bay Partnership – a CEO-led regional economic development organization with a mission to work with its partners to market the region nationally and internationally, to conduct regional research, and to coordinate efforts to influence business and government issues that impact economic growth and development.

Xcelience LLC is a premier provider of formulation development and clinical supplies solutions with a solid reputation for accelerating early phase clinical development. The company’s outstanding quality record, drug development expertise, disciplined project management, and willingness to customize enables delivery of real advantages to pharmaceutical innovators focused on small-molecule development. Partnering with a specialist for early development can accelerate development timelines and streamline the supply chain. Since 1997, Xcelience has been reliably expediting drug development and reducing compound risk. Company scientists have specialized experience in overcoming challenging physical and chemical properties while achieving improved solubility and compound bioavailability. For more information, visit www.xcelience.com.